Treatment and prevention of pulmonary conditions
First Claim
Patent Images
1. A liquid composition comprising a lung surfactant polypeptide, and at least one inhibitor of a mediator of tissue destruction.
1 Assignment
0 Petitions
Accused Products
Abstract
The invention provides compositions and methods for treating pulmonary conditions and for reducing the negative effects of pulmonary inflammation. Such compositions and methods employ protease inhibitors and a lung surfactant mixture. The compositions and methods can also include lipase inhibitors (e.g. a phospholipase inhibitors) and anti-oxidants.
-
Citations
131 Claims
- 1. A liquid composition comprising a lung surfactant polypeptide, and at least one inhibitor of a mediator of tissue destruction.
- 32. An aerosolized composition, comprising a lung surfactant polypeptide, and at least one inhibitor of a mediator of tissue destruction.
- 64. A method for treating pulmonary inflammation in a mammal comprising administering to the mammal a therapeutically effective amount of a composition comprising a lung surfactant polypeptide, and at least one inhibitor of a mediator of tissue destruction.
-
94. A composition for pulmonary delivery of an active agent to a patient, comprising a lung surfactant mixture and an active agent, wherein:
-
the lung surfactant mixture comprises a polypeptide having between 10-60 amino acid residues and an amino acid sequence of alternating hydrophobic and hydrophilic amino acid residue regions represented by the formula (ZaUb)cZd, wherein Z is a hydrophilic amino acid residue, U is a hydrophobic amino acid residue, a is an integer with an average value of 1-5, b is an integer with an average value of 3-20, c is an integer of about 1 to about 10, and d is an integer of about 0 to about 3. - View Dependent Claims (95, 96, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 109, 110, 111, 112, 113, 114)
-
-
97. The composition of claini 95, wherein the spreading agent is a fatty acid or fatty alcohol having a fatty acyl chain length of at least 12 carbon atoms.
-
115. An aerosolized composition for use in delivering an active agent to a patient via inhalation, comprising:
aerosol particles of a surfactant formulation, said particles having a mass median aerodynamic diameter in the 1-5 μ
m size range, said formulation being composed of (a) surfactant mixture containing (i) 50-95 dry weight percent phospholipid, (ii) 2-25 dry weight percent of a spreading agent effective to promote incorporation of the phospholipid into the surface lining layer of the lung, and (iii) 0.1 to 10 dry weight percent of lung-surfactant polypeptide having between 10-60 amino acid residues and an amino acid sequence of alternating hydrophobic and hydrophilic amino acid residue regions represented by the formula (ZaUb)cZd, where Z is a hydrophilic amino acid residue, U is a hydrophobic amino acid residue, a has an average value of 1-5, b has an average value of 3-20, c is 1-110, and d is 0 to 3, and (b) the active agent, in an amount between 1 and 80 weight percent of the dry weight of the surfactant formulation.- View Dependent Claims (116, 117, 118, 119, 120, 121, 122, 123, 124, 125, 126, 127, 128, 129, 130, 131)
Specification